BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Embrace the Outside: Exercises and Entertainment - 2Nature: 10 High priority Setting up camp Spots In Europe
- 3James Webb Space telescope spots 'big red dot' in the ancient universe: A ravenous supermassive black hole named 'BiRD'
- 4The Most Rousing Ladies Business visionaries of Today
- 5Wolf Bites Woman in Shocking Attack at Busy Shopping Center
- Instructions to Pick the Best Album Rates for Your Investment funds
- Ariana Grande and Jonathan Bailey will reunite for 'Sunday in the Park With George'
- German journalists' union condemns attack on reporters in village
- Figure out How to Protect Your Gold Venture from Unpredictability
- Quandoo to shut restaurant booking platform by end of 2026
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
- Choosing Moving Styles for Your Restroom Redesign
- 'You're no longer my sister' - rows erupt as war divides Iranian families
- Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
